Abstract | OBJECTIVES: METHODS: This was a cross-sectional study. Serum FGF23 levels were analysed in 152 patients and 34 healthy control individuals. Patients belonged to three groups: HIV-1-infected, antiretroviral-treated patients who have developed HALS (n = 60); HIV-1-infected, antiretroviral-treated patients without HALS (n = 43); and untreated (naive) HIV-1-infected patients (n = 49). Serum FGF23 levels were compared with lipid and glucose homeostasis parameters, fat distribution and cardiovascular risk. RESULTS: CONCLUSIONS: FGF23 levels are increased in HIV-1-infected patients, especially in those with HALS, and this increase is associated with dyslipidaemia, insulin resistance, metabolic syndrome, fat distribution and parameters of inflammation. FGF23 is not associated with cardiovascular risk when age is taken into account.
|
Authors | Pere Domingo, Maria Karuna Lamarca, José M Gallego-Escuredo, Ferran Torres, Joan C Domingo, Joan Villarroya, M Del Mar Gutierrez, M Gracia Mateo, Francesc Vidal, Francesc Villarroya, Marta Giralt |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 70
Issue 6
Pg. 1825-32
( 2015)
ISSN: 1460-2091 [Electronic] England |
PMID | 25700720
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: [email protected]. |
Chemical References |
- FGF23 protein, human
- Fibroblast Growth Factors
- Fibroblast Growth Factor-23
|
Topics |
- Adult
- Body Fat Distribution
- Cardiovascular Diseases
(epidemiology)
- Cross-Sectional Studies
- Female
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors
(blood)
- HIV Infections
(complications, pathology)
- Humans
- Male
- Metabolic Diseases
(epidemiology)
- Middle Aged
- Risk Assessment
|